SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells

  • Oncol Lett. 2014 Jul;8(1):367-373. doi: 10.3892/ol.2014.2083.
Ying Liu  1 ,  Zuan Zhu  2 ,  Hongxing Cai  3 ,  Qinghua Liu  1 ,  Honglian Zhou  2 ,  Zhengqiu Zhu  4
Affiliations
  • 1. Department of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
  • 2. Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
  • 3. Department of Forensic Medicine, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
  • 4. Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
PMID: 24959278 DOI: 10.3892/ol.2014.2083
Abstract

Cisplatin is frequently used in treating gastric cancers; however, acquired resistance to the drug often reduces the efficacy of therapy. The present study analyzed the efficacy of the combination of 4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol (SKI-II) and cisplatin [cis-diamminedichloroplatinum (II); DDP] on the gastric Cancer SGC7901/DDP cell line. The results revealed that SKI-II and DDP had a clear synergistic effect. Glutathione (GSH) and Glutathione S-transferase (GST) levels decreased significantly subsequent to the cells being treated with the combination of DDP and SKI-II compared with the cells that were treated with DDP or SKI-II alone. Phosphorylated extracellular-signal-regulated kinase (p-ERK) and phosphorylated c-Jun N-terminal kinase (p-JNK) expression levels also decreased following treatment with SKI-II. The results suggested that SKI-II is able to reverse the drug resistance in human gastric carcinoma cells and enhance the antitumor effect of DDP through the Ras/mitogen-activated protein kinase (MAPK) proliferation pathway.

Keywords
4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol; SGC7901/DDP cells; glutathione; glutathione S-transferase; mitogen-activated protein kinase pathway; sphingosine kinase 1.
Products